Previous studies of intravesical injection of radiolabelled antibodies directed against tumour‐associated antigens have successfully showed retention of antibodies within the tumour mass,21 suggesting that this could be a feasible route for delivery of anti‐PD‐1 antibodies in the setting of NMIBC. This evidence concerns the gene PDCD1 and neoplasm.